Weight and behavior with deflazacort
Deflazacort has a smaller suppressive effect on the
hypothalamic-pituitary adrenal (HPA) axis vs prednisone; considering a small concentration of deflazacort crosses the blood brain barrier reaching the HPA axis, a reduced risk of behavioral disorders has been hypothesized.6
Compared to those on prednisone, patients taking deflazacort in clinical trials were7
Less likely to gain weight
Less likely to experience psychiatric side effects (ie, abnormal behavior, aggression, irritability, and
Less likely to discontinue treatment due to side effects
Comparisons between deflazacort and prednisone are not included in the Prescribing Information for deflazacort because prednisone is not an approved treatment for DMD.